NeoSync
Company

Last deal

$13.M

Amount

Series D

Stage

10.08.2017

Date

1

all rounds

$13.M

Total amount

General

About Company
NeoSync, Inc. develops non-invasive neuromodulation products to treat Major Depressive Disorder and other CNS diseases using TMS technology.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Series D

IPO status

Private

Description

The company's personalized therapies use low energy, alternating magnetic field stimulation in daily 30-minute sessions to gently adjust a depressed brain toward a more normal state, enabling patients to quickly cure major depressive disorders and other diseases of the central nervous system. Led by experienced medical device executives and entrepreneurs, NeoSync's proprietary platform technology is being used to develop advanced, non-invasive neuromodulation products designed to treat a range of mental health disorders, including Autism, Parkinson's Disease, Anxiety, Post Traumatic Stress Disorder, and more.